JSM 2012 Online Program

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

Online Program Home


*9 !**	Sun, 7/29/2012, 2:00 PM - 3:50 PM	HQ-Sapphire EF
Journeys to Targeted Therapies and Personalized Medicines: Three Stories — Invited Papers
JSM 2012 Host Local Chapter - San Diego , Biopharmaceutical Section
Organizer(s): Christy Chuang-Stein, Pfizer Inc., Xin Huang, Pfizer Inc., Qiang Casey Xu, FDA
Chair(s): Christy Chuang-Stein, Pfizer Inc.
2:05 PM	Gefitinib from Phase I Responses to a Personalized Medicine — Anna Osmukhina, AstraZeneca ; Andrew Stone, AstraZeneca
2:30 PM	Alimta (Pemetrexed) as a Treatment for Nonsquamous, Nonsmall-Cell Lung Cancer — Patrick M Peterson, Eli Lilly and Company
2:55 PM	Xalkori® The First Prospectively Identified Precision Medicine for Treatment of Non-Small Cell Lung Cancer (NSCLC): Development Opportunities and Challenges — Paulina Selaru, Pfizer Inc. ; Yiyun Tang, Pfizer Inc. ; Bo Huang, Pfizer Inc.
3:20 PM	Discussant: Rajeshwari Sridhara, FDA
3:40 PM	Floor Discussion

2012 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.